logo
GMOs Made With New Techniques Face Low Adoption Rates and Market Failure

GMOs Made With New Techniques Face Low Adoption Rates and Market Failure

Yahoo17-06-2025
New international report examines the efficacy of 'New GMOs' despite billions in investment in CRISPR and similar technology
Brussels / Bellingham, Wash., June 17, 2025 (GLOBE NEWSWIRE) -- As political pressure mounts to deregulate gene-edited crops, a new report by the European Non-GMO Industry Association (ENGA) and the Non-GMO Project reveals a stark reality: New GMO crops created with newer genetic engineering techniques, such as CRISPR, ODM, TALEN, ZFN and RNAi, are failing to find growers and markets. Despite billions of dollars in investment and widespread deregulation, only three new gene-edited GMOs are currently in cultivation, and none of them meaningfully advance climate or sustainability goals. The report indicates that 49 more crops are in development.
The findings dismantle the narrative that New GMOs are essential to feeding a growing population or combating the climate crisis. In fact, the evidence suggests that their real-world impact remains negligible, and two early new crops have already been withdrawn from the market due to commercial failure.
'Despite the hype, the evidence from our report is overwhelming: New GMOs are only a promise and are far from a reality on the market,' said ENGA Secretary General, Heike Moldenhauer. 'Furthermore, despite widespread claims, not a single New GMO currently on the market delivers on sustainability promises, one of the main reasons their proponents are pushing to deregulate them.'
The report reveals:
Only three New GMO crops are being cultivated globally: two in the US and one in Japan.
Many of the 49 crops in development have been cleared for market access, especially in the US, but are not actually grown.
None of the New GMO crops in development meaningfully address climate resilience or biodiversity loss, with just two showing potential for drought or salt tolerance.
At the same time, the Non-GMO Project points out that continued monitoring is critical. GMO crops continue to be developed for cultivation using older transgenic engineering techniques to produce new crops like herbicide-resistant wheat and pest-resistant sugar cane. Additionally, many new GMOs are being created using synthetic biology and precision fermentation to create lab-grown foods like 'animal-free dairy' and seedless seed oils.
'To be sure, old GMOs are still an overwhelming presence in the food supply web, especially here in the United States, and more are on the way,' said Hans Eisenbeis, Director of Mission and Messaging at the Non-GMO Project. 'However, efforts to launch the next generation of GMO plants using gene-editing technologies like CRISPR just aren't getting off the ground, despite increasingly permissive regulations, exaggerated sustainability claims, and billions of dollars in public and private investment.'
The report highlights shifts in the development of New GMOs compared to their old counterparts. The application of old genetic engineering largely focused on five commodity crops: soy, corn, canola, sugar beets and cotton. These are used as animal feed, processed food ingredients, fuel or clothing. Today, the application of genetic engineering is far broader. With new technologies, companies are working on a variety of plants that are intended for direct human consumption, such as tomatoes and salad greens.
The report also shows that developers of New GMOs have become more diverse. Whereas old GMOs were mainly produced and marketed by the four engineering giants Corteva, Bayer, BASF and Syngenta, many start-up companies are involved in the development of New GMOs, as are state institutes. The new report lays out the regulatory hotspots around the world.
ENGA and the Non-GMO Project strongly recommend that companies in the food industry:
Explicitly exclude New GMOs in their supplier requirements.
Rely on independent certification systems that ensure products are free from New GMOs.
New GMOs are frequently "non-testable" meaning there are no commercially-available tests, so vigilance from the non-GMO community is critical.
New GMOs differ from traditional GMOs in that they may not rely on transgenic technologies or leave foreign DNA in the organism. In many countries, New GMOs face a simplified regulatory process and do not require safety testing.
Find the full report 'New GMOs' here.
###
Media Contacts:ENGA: Sarah Farndale, farnisarah@gmail.com +32 (0)490 390665Non-GMO Project : Alex Tursi, alex@weareguru.com, +1 802.777.6737
About the reportThe report's editors are: Hans Eisenbeis, The Non-GMO Project (USA), Eva Gelinsky, Researcher (CH) and Heike Moldenhauer, ENGA (BE).
About ENGAThe European Non-GMO Industry Association (ENGA) is the voice of the Non-GMO food and feed sector at the EU level. ENGA, founded in 2020, secures and supports the expansion of non-GMO production and advocates for the strict regulation of old and New GMOs in order to keep untested and unlabelled GMOs from entering the EU food and feed chains. https://www.enga.org
About The Non-GMO Project
The Non-GMO Project is a mission-driven nonprofit organization based in the US. Since 2007, the Non-GMO Project Verified seal has remained North America's most trusted third-party verification for GMO avoidance. Through its Food Integrity Collective, Non-UPF Verified program, and Non-GMO Project Verified mark, the organization promotes transparency and health in food systems. Learn more at foodintegritycollective.org, nonultraprocessed.org, and nongmoproject.org.
CONTACT: Alex Tursi Non-GMO Project 802-777-6737 alex@weareguru.comSign in to access your portfolio
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Business Upturn

time2 days ago

  • Business Upturn

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) — In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical. The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio's infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks. In parallel, Anbio is advancing the boundaries of decentralized molecular diagnostics with the launch of its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care. 'Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy,' said Michael Lau, CEO of Anbio Biotechnology. The AP-100 utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction. Its integrated design streamlines sample-to-result workflows, making it well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments. Key highlights: 15-minute PCR results from raw sample to answer Extraction-free workflow with no hazardous reagents Compact 668g device for mobile or near-patient testing Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV Lab-comparable accuracy validated against mainstream PCR platforms While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform. In line with its global infectious disease strategy, Anbio is expanding the assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV), extending its role from rapid outbreak response to sustained disease management. 'Whether it's vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat,' Lau added. With its combination of speed, mobility, and lab-grade precision, Anbio's new-generation POCT PCR system strengthens healthcare capacity in both well-resourced and resource-limited settings, advancing global preparedness for infectious disease threats. About Anbio Biotechnology Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide. For more information about Anbio Biotechnology, follow us for the latest news and updates. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Diabetic Man With Gene-Edited Cells Produces His Own Insulin—No Transplant Drugs Required
Diabetic Man With Gene-Edited Cells Produces His Own Insulin—No Transplant Drugs Required

Gizmodo

time3 days ago

  • Gizmodo

Diabetic Man With Gene-Edited Cells Produces His Own Insulin—No Transplant Drugs Required

A new case study offers a tantalizing glimpse into the potential future of transplantation medicine. A man with type 1 diabetes is now able to make his own insulin thanks to a transplant of gene-edited pancreatic cells—a transplant that hasn't required the typical drugs used to avoid rejection. Scientists in Sweden and the U.S. conducted the research, published this week in the New England Journal of Medicine. The 42-year-old man with long-standing diabetes was given donated islet cells that were genetically modified via CRISPR to prevent immune rejection. Roughly four months after the procedure, his fully gene-edited cells have continued to produce insulin without provoking an immune response. 'Our study, although preliminary, suggests that immune evasion is an alternative concept for the circumvention of allorejection,' the authors wrote in the paper. A New Diabetes Treatment Is on the Horizon—But It Involves Poop People with type 1 diabetes have immune systems that destroy the pancreatic cells responsible for making insulin. The condition can be managed with regular doses of synthetic insulin, but people's health still tends to worsen over time. Recently, scientists have been studying whether donated islet cell transplants can provide a self-sustained replacement supply of insulin for type 1 diabetics—an effective cure, in other words, provided the cells can survive long-term. Early clinical trials of the technology have looked promising so far, but these transplants still require lifelong immunosuppressive therapy to ensure the host's body doesn't go after the donated cells. Effective as these drugs are, they have their well-known drawbacks, such as weakening people's immunity to actual threats like infections. The study researchers have been experimenting with a unique approach to sidestep the need for these drugs. They first tested it on mice and monkeys, with this new case being the first test in humans. They created three specific edits in the donated cells, all intended to quiet the most likely responses from the immune system. Two of the edits deplete the cells' supply of HLA class I and II antigens, proteins that tell our T cells whether another cell is foreign or not. A third edit causes the donated cells to make more of another protein called CD47 that inhibits the activity of other immune cells that would normally target them. The researchers injected the modified cells into the man's forearm. The edits weren't completely successful in some of the cells, and the man's immune system quickly killed off these cells. But as hoped, his body left the fully edited cells alone, even without immunosuppressants. The surviving cells produced insulin as normal, and the man appeared to be doing well 12 weeks later. He did experience several adverse events, but none were serious or linked to the transplanted cells themselves (he had mildly inflamed veins where a catheter was placed, for instance). This study is only a proof of concept, geared more at showing the procedure can be done safely than at proving it actually works. The man was given a relatively low dose of the donated cells, likely too low for his body to produce enough insulin on its own to no longer need treatment. Follow-up is also needed to know whether these cells can survive long-term. In Medical First, Woman's Type 1 Diabetes Seemingly Cured by Stem Cells But there's much to be encouraged about. And it's the latest sign that scientists are truly on the verge of making type 1 diabetes curable. Other research teams have shown early success in using similar transplants to cure the condition, including some that have also avoided needing immunosuppressant therapy.

Strategic News: Digital Pathology Market to Hit $2.75B by 2030
Strategic News: Digital Pathology Market to Hit $2.75B by 2030

Business Upturn

time4 days ago

  • Business Upturn

Strategic News: Digital Pathology Market to Hit $2.75B by 2030

By GlobeNewswire Published on August 7, 2025, 17:30 IST Delray Beach, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) — The global digital pathology market, valued at US$1.30 billion in 2024 stood at US$1.46 billion in 2025 and is projected to advance at a resilient CAGR of 13.5% from 2025 to 2030, culminating in a forecasted valuation of US$2.75 billion by the end of the period. This rapid expansion is driven by increasing demand for telepathology, AI-powered diagnostics, and the ongoing digital transformation of healthcare diagnostics. As pathology shifts from analog to digital workflows, healthcare organizations, research institutes, and life sciences companies are accelerating adoption to enhance efficiency, collaboration, and diagnostic precision. Download PDF Brochure: What's Fueling the Digital Pathology Market Growth? Rising Need for Telepathology: Pathologists can now remotely analyze slides, accelerating turnaround times and enabling real-time collaboration. AI Integration: Artificial Intelligence is transforming image analysis, aiding in faster, more accurate diagnostics and predictive insights. Strategic Collaborations: For example, the March 2024 partnership between Amazon Web Services (AWS) and Philips supports secure, cloud-based digital pathology platforms. Chronic Disease Burden: Rising cancer cases and complex chronic conditions are pushing healthcare systems to adopt digital pathology for better diagnostics and treatment planning. Market Segmentation Insights By Type: Why is Human Pathology Leading? The human pathology segment is experiencing the fastest growth due to: Increased demand for faster, accurate diagnostics Chronic disease prevalence (especially cancer) Benefits such as image sharing, remote collaboration, and reduced physical storage Compared to traditional methods, digital pathology streamlines workflows and supports multidisciplinary decision-making. By End User: Why Are Pharma & Biotech Companies Dominating? In 2024, pharmaceutical and biotechnology companies led the market due to: Growing drug discovery and personalized medicine needs Use of high-resolution imaging and automated screening for faster preclinical and clinical evaluations Accelerated development of AI-assisted diagnostics By Region: Why is North America Leading? North America accounted for the largest market share in 2024, backed by: Advanced healthcare IT infrastructure High R&D investments and strategic initiatives Presence of leading pathology labs and academic institutions A strong push for digital health technologies and early adoption in the US Request Sample Pages : People Also Ask: Top W-Questions for Digital PathologyQ. What is driving the digital pathology market growth?A. The combination of telehealth expansion, AI-powered image analysis, and demand for remote diagnostics is accelerating market growth.Q. How does digital pathology benefit hospitals and labs?A. It improves workflow efficiency, enables remote collaboration, speeds up diagnostics, and reduces operational costs.Q. Which companies are leading the digital pathology space?A. Top players include Danaher, Philips, Roche, Hamamatsu, Indica Labs, and PathAI, each advancing innovation and global adoption.Q. What challenges does the digital pathology market face? A. Key hurdles include high initial investment costs, a shortage of skilled pathologists, and varied reimbursement policies across regions. Key Companies Shaping the Digital Pathology Industry Danaher Corporation (US) Through its subsidiary Leica Biosystems, Danaher offers end-to-end solutions from biopsy to cancer diagnostics. Highlights include: 2023 partnership with Paige AI for next-gen AI-based diagnostics Strategic collaboration with ESDIP to accelerate European adoption AI-powered platforms for hospitals and labs to streamline workflows Koninklijke Philips N.V. (Netherlands) Philips leads the transition from analog to digital with: 15–20% per-case efficiency gains Tools for real-time collaboration and remote consultations Solutions implemented in over 300 institutions and 20+ labs globally 2024 partnership with AWS to integrate secure, cloud-based workflows Other Prominent Players Include: Roche (Switzerland) Indica Labs (US) PathAI (US) Fujifilm Holdings (Japan) Hamamatsu Photonics (Japan) 3DHISTECH (Hungary) Akoya Biosciences (US) Proscia (US) Sectra AB (Sweden) Aiforia (Finland) Hologic (US) Glencoe Software (US) XIFIN (US) Motic Digital Pathology (US) OptraSCAN (US) Kanteron Systems (Spain) Final Takeaway: Why Digital Pathology is the Future of DiagnosticsThe digital pathology market is no longer emerging — it's transforming the way diagnostics are conducted. With AI integration, collaborative platforms, and global partnerships, this industry is enabling faster, smarter, and more connected care. As healthcare systems seek precision, scalability, and efficiency, digital pathology is fast becoming an essential part of the modern diagnostic ecosystem. For more information, Inquire Now! Explore Adjacent Healthcare Reports: AI in Pathology Market Computer Vision in Healthcare Market Healthcare IT Market Dental Digital X-ray Market Tissue Diagnostics Market Get access to the latest updates on Digital Pathology Companies and Digital Pathology Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store